Radiosensitization of Multiple Brain Metastases Using AGuIX Gadolinium Based Nanoparticles (NANO-RAD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02820454|
Recruitment Status : Recruiting
First Posted : July 1, 2016
Last Update Posted : October 5, 2017
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. AGuIX particles may increase the effectiveness of radiation therapy by making tumor cells more sensitive to radiation.
PURPOSE: This first-in-man Phase I trial will study the side effects and best dose of AGuIX when injected together with whole brain radiation therapy in treating patients with multiple brain metastases. The effectiveness of the combination of AGuIX and radiation therapy will be also assessed.
|Condition or disease||Intervention/treatment||Phase|
|Brain Metastases||Drug: AGuIX Radiation: whole brain radiation therapy||Phase 1|
The present study will investigate the safety, tolerability and spectrum of side effects of AGuIX in combination with whole brain radiation therapy. As such, this study will characterize the dose limiting toxicities (DLT) and maximum tolerated dose (MTD) of in combination with whole brain radiation therapy in patients with multiple brain metastases.
On day 1, patients will receive a single intravenous injection of AGuIX. An MRI scan will be performed 2 hours after injection to visualize the distribution of AGuIX in brain metastases and surrounding healthy tissue, and to evaluate the contrast enhancement in brain metastases. Then patients will undergo a whole brain radiation therapy, starting 4 hours after AGuIX injection, up to completion of 2 weeks, 5 days a week of treatment (30Gy, 3Gy/fraction).
During the first 24h after injection, several blood draws will be also performed in order to assess the pharmacokinetic of AGuIX.
After completion of study treatment, patients will be followed periodically.
Patients will be enrolled in cohorts and will be treated at sequentially rising dose levels of AGuIX combined with whole brain radiation therapy. Three subjects will initially enter at each dose. If none of the three experiences a dose-limiting toxicity we will proceed to the next dose. If one of the three experiences that level of toxicity, we will accrue 3 more subjects at that dose. If at any time there are two or more dose-limiting toxicities (in the 3-6 subjects) on a given dose, we will drop down to a lower dose. Dose escalation will continue until the MTD of AGuIX and whole brain radiation therapy is established. The MTD will then be one dose below the DLT occurring in at least 1 out of 3 subjects (2 out of 6 patients).
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||18 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Etude Clinique de Phase I de Radiosensibilisation de métastases cérébrales Par Nanoparticules de Gadolinium|
|Actual Study Start Date :||June 2016|
|Estimated Primary Completion Date :||February 2018|
|Estimated Study Completion Date :||December 2018|
Experimental: AGuIX and radiotherapy
Patients receive a single intravenous injection of AGuIX on day 1. Then patients undergo a whole brain radiation therapy, 5 days a week in weeks 1-2. The first radiotherapy session will be performed 4 hours after AGuIX injection.
Five dose escalation cohorts : 15 mg/kg, 30mg/kg, 50mg/kg, 75mg/kg and 100 mg/kg
A single intravenous injection on day 1. Dose level 1: 15mg/kg; Dose level 2: 30mg/kg, Dose level 3: 50mg/kg; Dose level 4: 75mg/kg; Dose level 5: 100mg/kg
Other Name: Nano-sized gadolinium particlesRadiation: whole brain radiation therapy
30Gy in 10 sessions of 3Gy (5 days a week in weeks 1-2); first session 4 hours after AGuIX injection.
- Maximum-tolerated dose (MTD) of polysiloxane gadolinium-chelates based nanoparticles (AGuIX) given concurrently to the whole brain radiation therapy for the treatment of multiple brain metastases [ Time Frame: 18 months ]To determine Maximum-tolerated dose (MTD) of polysiloxane gadolinium-chelates based nanoparticles (AGuIX) given concurrently to the whole brain radiation therapy, according to incidence of dose limiting toxicity (DLT) graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03
- Pharmacokinetic characteristics of AGuIX particles after intravenous injection [ Time Frame: 18 months ]Cmax
- Pharmacokinetic characteristics of AGuIX particles after intravenous injection [ Time Frame: 18 months ]AUC
- Pharmacokinetic characteristics of AGuIX particles after intravenous injection [ Time Frame: 18 months ]T1/2
- Distribution of AGuIX particles in brain metastases and surrounding healthy tissue evaluated by MRI [ Time Frame: 30 months ]Measure of the T1 contrast enhancement in brain metastases and surrounding healthy tissue after intravenous administration of AGuIX particles
- Intracranial progression-free survival [ Time Frame: 12 months after radiation ]The intracranial progression-free survival will be assessed by MRI (1,3, 6, 9 and 12 months from the date of discovery of the metastases)
- Overall survival [ Time Frame: 30 months ]The overall survival will be assessed starting from the date of discovery of the metastases
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02820454
|Contact: Camille VERRY, MD||33 4 76 76 54 email@example.com|
|Contact: Géraldine Le Duc, PhD||33 6 87 12 10 firstname.lastname@example.org|
|University Hospital Grenoble||Recruiting|
|Grenoble, France, 38100|
|Contact: Camille VERRY CVerry@chu-grenoble.fr|
|Principal Investigator:||Camille VERRY, MD||University Hospital, Grenoble|